Remove Hemorrhage Remove Outcomes Remove Thrombosis
article thumbnail

Abelacimab Stops Bleeding, But Stroke Impact Uncertain

CardiacWire

Current guidelines recommend direct-acting oral anticoagulants (DOACs) for AF because they reduce ischemic stroke with a lower risk of brain hemorrhage. By inhibiting Factor XI (an anticoagulation enzyme), drugs like abelacimab potentially prevent thrombosis without increasing spontaneous bleeding risks.

Stroke 59
article thumbnail

Abstract TP180: Characteristics and Outcomes of Cerebral Venous Sinus Thrombosis Associated With COVID-19

Stroke Journal

Background:Coronavirus disease 2019 (COVID-19) increases the risk of cerebral venous sinus thrombosis (CVST), and previous reports derived from small case series reported a high mortality in these patients, up to 40%. Median age did not differ between the groups (43 vs 44years,P=0.6)

article thumbnail

Abstract 005: Outcomes of Heparin Induced Thrombocytopenia Type II in Aneurysmal Subarachnoid Hemorrhage Patients

Stroke: Vascular and Interventional Neurology

Both anticoagulants can be used intraoperatively and postoperatively for DVT prophylaxis in patients undergoing subarachnoid hemorrhage (SAH) treatment. Patients from both groups were assessed for baseline clinical characteristics, comorbidities, interventions, complications, and outcomes.

article thumbnail

Abstract WP149: Duration of Lead-In Parenteral Therapy and Outcomes in Individuals Treated With DOAC for Cerebral Venous Thrombosis: The ACTION-CVT Study

Stroke Journal

Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). We examined duration of PA prior to DOAC initiation and outcomes in ACTION-CVT, an international retrospective study.Methods:We compared three groups: no lead-in PA, 1-4 days (d) of PA, and 5-21d of PA. 1-4d, 23.8%

article thumbnail

Abstract TMP62: The Delayed Seizure CVT Score Predicts Delayed Seizure After Cerebral Venous Thrombosis - A Secondary Analysis of ACTION-CVT

Stroke Journal

Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis. Risk factors included intracranial hemorrhage (OR 2.0

article thumbnail

Daytime DNase-I Administration Protects Mice From Ischemic Stroke Without Inducing Bleeding or tPA-Induced Hemorrhagic Transformation, Even With Aspirin Pretreatment

Stroke Journal

Neutrophil extracellular traps (NETs), associated with poor outcomes and reperfusion resistance, contribute to thrombosis. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy. DNase-I caused no bleeding or impact on HT induced by late tPA.

article thumbnail

Abstract TMP85: Radiographic severity is associated with moderate to severe neurodevelopmental impairment in survivors of neonatal deep medullary vein thrombosis.

Stroke Journal

However, long-term outcomes remain poorly described, and the prognostic significance of the radiographic findings is uncertain.Methods:We extracted demographics and clinical variables for all infants with DMVT at our institution from 2007 to 2023. Stroke, Volume 56, Issue Suppl_1 , Page ATMP85-ATMP85, February 1, 2025.